Postnatal dexamethasone: what is the real cost-benefit ratio?
- PMID: 12948061
Postnatal dexamethasone: what is the real cost-benefit ratio?
Abstract
Postnatal corticosteroids given early after birth reduce the risk of chronic lung disease in preterm infants but are associated with an approximate doubling of the risk of adverse neurosensory outcomes. Corticosteroids given after 7-10 d of age appear not to have these increased risks of neurosensory sequelae and reduce time on the ventilator.
Conclusion: Further research is needed to determine the lowest dose of corticosteroid that will improve lung function and minimize risks to the developing brain.
Comment on
-
Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year follow-up of cardiopulmonary function and growth.Acta Paediatr. 2003 Aug;92(8):896-904. Acta Paediatr. 2003. PMID: 12948063 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical